These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15009322)

  • 21. Scleroderma associated with anemia and thrombocytopenia that responded well to cyclosporin.
    Kamada K; Kobayashi Y; Katada K; Takahashi Y; Chikayama S; Ikeda M; Kondo M
    Acta Haematol; 2000; 104(2-3):106-9. PubMed ID: 11154984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis.
    Low AH; Lee P
    J Rheumatol; 2008 Nov; 35(11):2286. PubMed ID: 19004063
    [No Abstract]   [Full Text] [Related]  

  • 23. Comorbidity influences therapeutic approach in multiple sclerosis.
    Capone F; Ferraro E; Florio L; Marcoccia A; Di Lazzaro V; Di Battista G
    Clin Neurol Neurosurg; 2017 Apr; 155():14-16. PubMed ID: 28212926
    [No Abstract]   [Full Text] [Related]  

  • 24. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
    Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
    Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclophosphamide in systemic sclerosis: light and shadows.
    Vlachoyiannopoulos PG; Ioannidis JP
    Clin Exp Rheumatol; 2004; 22(5):551-2. PubMed ID: 15485005
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis.
    Khader A; Valiaveetil B; Nalini SD; George B; Sasidharanpillai S; Nazeer MMA; Manikath N
    Indian J Dermatol Venereol Leprol; 2021; 87(5):728-731. PubMed ID: 34379952
    [No Abstract]   [Full Text] [Related]  

  • 27. Success of prednisone in the treatment of a patient with sarcoidosis and systemic sclerosis: Report of a case.
    Borges da Costa J; Mayer-da-Silva A; Soares de Almeida LM; Marques Gomes M
    Dermatol Online J; 2009 Mar; 15(3):11. PubMed ID: 19379655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unusual association of systemic sclerosis and ankylosing spondylitis.
    Soledade CS; Sampaio-Barros PD; Samara AM; Marques-Neto JF
    Clin Rheumatol; 2005 Nov; 24(6):652-4. PubMed ID: 15338450
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical images: Voluminous ectopic tumoral calcinosis of the spine in systemic sclerosis.
    Durant C; Farge-Bancel D
    Arthritis Rheum; 2011 Feb; 63(2):411. PubMed ID: 20890973
    [No Abstract]   [Full Text] [Related]  

  • 30. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
    Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
    Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observational data to study medication outcomes in systemic sclerosis.
    Hudson M; Baron M; ; Steele R
    J Rheumatol; 2011 Mar; 38(3):575-7. PubMed ID: 21362793
    [No Abstract]   [Full Text] [Related]  

  • 32. [Advances in the treatment of scleroderma].
    Marquet R; Vilardell M
    Med Clin (Barc); 1984 Jun; 83(2):74-7. PubMed ID: 6147448
    [No Abstract]   [Full Text] [Related]  

  • 33. Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients.
    Becker MO; Schohe A; Weinert K; Huscher D; Schneider U; Burmester GR; Riemekasten G
    Ann Rheum Dis; 2012 Dec; 71(12):2061-2. PubMed ID: 22689320
    [No Abstract]   [Full Text] [Related]  

  • 34. What can we learn from negative clinical trials in systemic sclerosis?
    Veale DJ
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S1-4. PubMed ID: 20576207
    [No Abstract]   [Full Text] [Related]  

  • 35. Haemopoietic stem-cell transplantation for systemic sclerosis.
    Sullivan KM; Wigley FM; Denton CP; van Laar JM; Furst DE
    Lancet; 2012 Jan; 379(9812):219; author reply 219-20. PubMed ID: 22265628
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of cyclosporin A in systemic sclerosis.
    Gisslinger H; Burghuber OC; Stacher G; Schwarz W; Punzengruber C; Graninger W; Luger TA; Wolff K; Smolen JS
    Clin Exp Rheumatol; 1991; 9(4):383-90. PubMed ID: 1934687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of intractable scleromyxedema with cyclosporin A.
    Saigoh S; Tashiro A; Fujita S; Matsui M; Shibata S; Takeshita H; Duan H; Moroi Y; Urabe K; Koga T; Furue M
    Dermatology; 2003; 207(4):410-1. PubMed ID: 14657639
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe cardiac involvement in children with systemic sclerosis and myositis.
    Quartier P; Bonnet D; Fournet JC; Bodemer C; Acar P; Ouachée-Chardin M; Le Bidois J; Prieur AM
    J Rheumatol; 2002 Aug; 29(8):1767-73. PubMed ID: 12180742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Generalized scleroderma. Treatment with immunosuppressive agents].
    Saporta L; Godeau P; Delrieu F; Delbarre F
    Nouv Presse Med; 1972 Jul; 1(29):1929-30. PubMed ID: 5053601
    [No Abstract]   [Full Text] [Related]  

  • 40. The treatment of systemic sclerosis.
    Black CM
    Adv Exp Med Biol; 1999; 455():271-7. PubMed ID: 10599354
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.